Pancreatic Cancer Research

ResearcherMedical University of South CarolinaActive in the last 2 years

Julie B. Siegel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9635-5759; OpenAlex author ID A5072619313. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

  1. A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Co-author DOI 10.3390/antib13040101↗
  2. Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis. Co-author DOI 10.3233/cbm-220044↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nancy Klauber‐DeMore · 2 shared papers, 2023–2024 · strength 0.35
  2. John P O'Bryan · 2 shared papers, 2023–2024 · strength 0.35
  3. Nathan G. Dolloff · 2 shared papers, 2023–2024 · strength 0.35
  4. Reeder McNeil Robinson · 1 shared paper, 2024 · strength 0.20
  5. Rachel A. Burge · 1 shared paper, 2024 · strength 0.20
  6. Benjamin N. Christopher · 1 shared paper, 2024 · strength 0.20
  7. G. Aaron Hobbs · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.